Literature DB >> 33710585

Pathophysiology and Management of Variceal Bleeding.

Saleh A Alqahtani1,2, Sunguk Jang3.   

Abstract

Cirrhosis is the fifth leading cause of death in adults. Advanced cirrhosis can cause significant portal hypertension (PH), which is responsible for many of the complications observed in patients with cirrhosis, such as varices. If portal pressure exceeds a certain threshold, the patient is at risk of developing life-threatening bleeding from varices. Variceal bleeding has a high incidence among patients with liver cirrhosis and carries a high risk of mortality and morbidity. The management of variceal bleeding is complex, often requiring a multidisciplinary approach involving pharmacological, endoscopic, and radiologic interventions. In terms of management, three stages can be considered: primary prophylaxis, active bleeding, and secondary prophylaxis. The main goal of primary and secondary prophylaxis is to prevent variceal bleeding. However, active variceal bleeding is a medical emergency that requires swift intervention to stop the bleeding and achieve durable hemostasis. We describe the pathophysiology of cirrhosis and PH to contextualize the formation of gastric and esophageal varices. We also discuss the currently available treatments and compare how they fare in each stage of clinical management, with a special focus on drugs that can prevent bleeding or assist in achieving hemostasis.

Entities:  

Year:  2021        PMID: 33710585     DOI: 10.1007/s40265-021-01493-2

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  139 in total

Review 1.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Authors:  Gennaro D'Amico; Guadalupe Garcia-Tsao; Luigi Pagliaro
Journal:  J Hepatol       Date:  2005-11-09       Impact factor: 25.083

Review 2.  Management of decompensated cirrhosis.

Authors:  Dina Mansour; Stuart McPherson
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

3.  [Epidemiology and natural history of cirrhosis].

Authors:  Sylvie Naveau; Gabriel Perlemuter; Axel Balian
Journal:  Rev Prat       Date:  2005-09-30

Review 4.  Hepatic fibrosis. Correlation of biochemical and morphologic investigations.

Authors:  H Popper; S Uenfriend
Journal:  Am J Med       Date:  1970-11       Impact factor: 4.965

5.  Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction.

Authors:  G Gabbiani; G B Ryan; G Majne
Journal:  Experientia       Date:  1971-05-15

Review 6.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

Review 7.  Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

Authors:  Jaume Bosch; Juan G Abraldes; Mercedes Fernández; Juan Carlos García-Pagán
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

Review 8.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

9.  Hepatic wound repair.

Authors:  Maurizio Parola; Massimo Pinzani
Journal:  Fibrogenesis Tissue Repair       Date:  2009-09-25

10.  The etiology of upper gastrointestinal bleeding in cirrhotic patients.

Authors:  Anca Alexandra Romcea; Marcel Tanţău; Andrada Seicean; Oliviu Pascu
Journal:  Clujul Med       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.